In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal Statistics, Q2 2015

A look at financing, M&A and alliance activity April–June 2015

Executive Summary

At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

Advertisement

Related Content

Ophthalmology Surgeons, Companies Finding Solutions In Medtech
US Neurostimulation Devices Market Forecast to Grow By $1B+ With New Indications, New Technologies
Newly Public Glaukos Unveils Vision For The MIGS Market
Integra Expands Wound Care Infrastructure With TEI Buy
Autonomic Technologies Raises $38M For On-Demand Neurostim
PAD-Focused Medtechs Eye Golden Period In Growing Silver Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel